Ozari Health Expands Tirzepatide Compounding Pharmacy Network to Five US-Licensed 503A Pharmacies
New York, NY, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ozari Health , a national telehealth platform for compounded GLP-1 treatment, today announced that its tirzepatide compounding…
DO
By Daniel Okafor · Regulatory Correspondent
Nov 3 11:24 ETSource: markets.businessinsider.com
From the source
Read at markets.businessinsider.comOzari Health Expands Tirzepatide Compounding Pharmacy Network to Five US-Licensed 503A Pharmacies
New York, NY, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ozari Health , a national telehealth platform for compounded GLP-1 treatment, today announced that its tirzepatide compounding pharmacy network has grown from two to five US-licensed 503A sterile compounding pharmacies, each named publicly on the company's pharmacy standards page . The expansion accompanies the launch of the company's two plans, Ozar
